Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2023 · 10-Q
Revenue$22.56M$22.56M+30.7% vs Q1 2022 Net Income-$1.90M-$1.90MN/M vs Q1 2022 EPS Diluted-$0.03-$0.03N/M vs Q1 2022 Gross Profit$13,518,000+28.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow$2,792,000N/M Margins · derivedGross margin59.9%−1.1 pt vs Q1 2022
Operating margin-8.7%+36.1 pt vs Q1 2022
Net margin-8.4%+36.4 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end